Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cummings J. L., Cyrus P. A., Bieber F., Mas J., Orazem J., Gulanski B. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group. Neurology. 1998 May;50(5):1214–1221. doi: 10.1212/wnl.50.5.1214. [DOI] [PubMed] [Google Scholar]
- Davies P., Maloney A. J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976 Dec 25;2(8000):1403–1403. doi: 10.1016/s0140-6736(76)91936-x. [DOI] [PubMed] [Google Scholar]
- Folstein M. F., Folstein S. E., McHugh P. R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189–198. doi: 10.1016/0022-3956(75)90026-6. [DOI] [PubMed] [Google Scholar]
- Morris J. C., Cyrus P. A., Orazem J., Mas J., Bieber F., Ruzicka B. B., Gulanski B. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology. 1998 May;50(5):1222–1230. doi: 10.1212/wnl.50.5.1222. [DOI] [PubMed] [Google Scholar]
- Nordberg A., Svensson A. L. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Saf. 1998 Dec;19(6):465–480. doi: 10.2165/00002018-199819060-00004. [DOI] [PubMed] [Google Scholar]
- Pitchumoni S. S., Doraiswamy P. M. Current status of antioxidant therapy for Alzheimer's Disease. J Am Geriatr Soc. 1998 Dec;46(12):1566–1572. doi: 10.1111/j.1532-5415.1998.tb01544.x. [DOI] [PubMed] [Google Scholar]
- Rogers S. L., Farlow M. R., Doody R. S., Mohs R., Friedhoff L. T. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998 Jan;50(1):136–145. doi: 10.1212/wnl.50.1.136. [DOI] [PubMed] [Google Scholar]
- Rogers S. L., Friedhoff L. T. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol. 1998 Feb;8(1):67–75. doi: 10.1016/s0924-977x(97)00079-5. [DOI] [PubMed] [Google Scholar]
- Rother M., Erkinjuntti T., Roessner M., Kittner B., Marcusson J., Karlsson I. Propentofylline in the treatment of Alzheimer's disease and vascular dementia: a review of phase III trials. Dement Geriatr Cogn Disord. 1998 Jul;9 (Suppl 1):36–43. doi: 10.1159/000051188. [DOI] [PubMed] [Google Scholar]
- Sano M., Ernesto C., Thomas R. G., Klauber M. R., Schafer K., Grundman M., Woodbury P., Growdon J., Cotman C. W., Pfeiffer E. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med. 1997 Apr 24;336(17):1216–1222. doi: 10.1056/NEJM199704243361704. [DOI] [PubMed] [Google Scholar]
- Seiger A., Nordberg A., von Holst H., Bäckman L., Ebendal T., Alafuzoff I., Amberla K., Hartvig P., Herlitz A., Lilja A. Intracranial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy. Behav Brain Res. 1993 Nov 30;57(2):255–261. doi: 10.1016/0166-4328(93)90141-c. [DOI] [PubMed] [Google Scholar]
- Summers W. K., Viesselman J. O., Marsh G. M., Candelora K. Use of THA in treatment of Alzheimer-like dementia: pilot study in twelve patients. Biol Psychiatry. 1981 Feb;16(2):145–153. [PubMed] [Google Scholar]